Peter C. Tyler

Peter C. Tyler

Auto-generated profile, based on publicly available information

Peter C. Tyler

Ferrier Research Institute

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RMRebecca L. Miller
Rebecca L. Miller
SGScott E. Guimond
Scott E. Guimond
RSRalf Schwörer
Ralf Schwörer
Olga ZubkovaOlga Zubkova
Olga Zubkova
PTPeter C. Tyler
Peter C. Tyler
KPKevin Pagel
Kevin Pagel
Despite evident regulatory roles of heparan sulfate (HS) saccharides in numerous biological processes, definitive information on the bioactive sequences of these polymers is lacking, with only a handful of natural structures sequenced to date. Here, we develop a “Shotgun” Ion Mobility Mass Spectrometry Sequencing (SIMMS2) method in which intact HS saccharides are dissociated in an ion mobility mass spectrometer and collision cross section values of fragments measured. Matching of data for intact and fragment ions against known values for 36 fully defined HS saccharide structures (from di- to decasaccharides) permits unambiguous sequence determination of validated standards and unknown natural saccharides, notably including variants with 3O-sulfate groups. SIMMS2 analysis of two fibroblast growth factor-inhibiting hexasaccharides identified from a HS oligosaccharide library screen demonstrates that the approach allows elucidation of structure-activity relationships. SIMMS2 thus overcomes the bottleneck for decoding the informational content of functional HS motifs which is crucial for their future biomedical exploitation.

5 December 2017 in ACS Infectious Diseases
Verified
Journal Article
Closed access
GEGary B. Evans
Gary B. Evans
PTPeter C. Tyler
Peter C. Tyler
VSVern L. Schramm
Vern L. Schramm

5 July 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TPTruc V. Pham
Truc V. Pham
AMAndrew Murkin
Andrew Murkin
MMMargaret M. Moynihan
Margaret M. Moynihan
LHLawrence Harris
Lawrence Harris
PTPeter C. Tyler
Peter C. Tyler
TMThomas D. Meek
Thomas D. Meek
Significance: Tuberculosis, caused byMycobacterium tuberculosis(Mtb) bacteria, is the most prevalent infectious disease, affecting one-third of the global population, especially in developing countries. First-line therapies to treat this disease are losing efficacy due to the emergence of drug resistance. Accordingly, new therapeutic agents of novel mechanisms of action remain an urgent medical need. The isocitrate lyases (ICL1 and ICL2) comprise metabolically essential enzymes ofMtb, are absent in mammals, and thereby provide therapeutically important drug targets for tuberculosis. Here, we describe the first example of a mechanism-based inactivator of ICL1 and ICL2 that could provide a starting point for the development of new drugs to treat tuberculosis.

23 November 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GBGabriel T. Bedard
Gabriel T. Bedard
NGNord Gilaj
Nord Gilaj
KPKarina Peregrina
Karina Peregrina
IBIsabella Brew
Isabella Brew
ETElena Tosti
Elena Tosti
VSVern L. Schramm
Vern L. Schramm
Homozygous 5'-methylthioadenosine phosphorylase (MTAP) deletions occur in approximately 15% of human cancers. Co-deletion of MTAP and methionine adenosyltransferase 2 alpha (MAT2a) induces a synthetic lethal phenotype involving protein arginine methyltransferase 5 (PRMT5) inhibition. MAT2a inhibitors are now in clinical trials for genotypic MTAP-/- cancers, however the MTAP-/- genotype represents fewer than 2% of human colorectal cancers (CRCs), limiting the utility of MAT2a inhibitors in these and other MTAP+/+ cancers. Methylthio-DADMe-immucillin-A (MTDIA) is a picomolar transition state analog inhibitor of MTAP that renders cells enzymatically MTAP-deficient to induce the MTAP-/- phenotype. Here, we demonstrate that MTDIA and MAT2a inhibitor AG-270 combination therapy mimics synthetic lethality in MTAP+/+ CRC cell lines with similar effects in mouse xenografts and without adverse histology on normal tissues. Combination treatment is synergistic with a 104-fold increase in drug potency for inhibition of CRC cell growth in culture. Combined MTDIA and AG-270 decreases S-adenosyl-L-methionine and increases 5'-methylthioadenosine in cells. The increased intracellular methylthioadenosine:S-adenosyl-L-methionine ratio inhibits PRMT5 activity, leading to cellular arrest and apoptotic cell death by causing MDM4 alternative splicing and p53 activation. Combination MTDIA and AG-270 treatment differs from direct inhibition of PRMT5 by GSK3326595 by avoiding toxicity caused by cell death in the normal gut epithelium induced by the PRMT5 inhibitor. The combination of MTAP and MAT2a inhibitors expands this synthetic lethal approach to include MTAP+/+ cancers, especially the remaining 98% of CRCs without the MTAP-/- genotype.

27 November 2018 in ACS Chemical Biology
Verified
Journal Article
Closed access
Olga ZubkovaOlga Zubkova
Olga Zubkova
YAYassir A. Ahmed
Yassir A. Ahmed
SGScott E. Guimond
Scott E. Guimond
SNSophia-Louise Noble
Sophia-Louise Noble
JMJohn Miller
John Miller
JTJeremy E. Turnbull
Jeremy E. Turnbull

23 October 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SWShanzhi Wang
Shanzhi Wang
SCScott A Cameron
Scott A Cameron
KCKeith Clinch
Keith Clinch
GEGary B. Evans
Gary B. Evans
ZWZhimeng Wu
Zhimeng Wu
PTPeter C. Tyler
Peter C. Tyler